IL141762A0 - New oral formulations - Google Patents

New oral formulations

Info

Publication number
IL141762A0
IL141762A0 IL14176299A IL14176299A IL141762A0 IL 141762 A0 IL141762 A0 IL 141762A0 IL 14176299 A IL14176299 A IL 14176299A IL 14176299 A IL14176299 A IL 14176299A IL 141762 A0 IL141762 A0 IL 141762A0
Authority
IL
Israel
Prior art keywords
oral formulations
new oral
new
rivastigamine
releasing
Prior art date
Application number
IL14176299A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27547321&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL141762(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821299.6A external-priority patent/GB9821299D0/en
Priority claimed from GBGB9821298.8A external-priority patent/GB9821298D0/en
Priority claimed from GBGB9826654.7A external-priority patent/GB9826654D0/en
Priority claimed from GBGB9827624.9A external-priority patent/GB9827624D0/en
Priority claimed from GBGB9907822.2A external-priority patent/GB9907822D0/en
Priority claimed from GBGB9907823.0A external-priority patent/GB9907823D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL141762A0 publication Critical patent/IL141762A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL14176299A 1998-10-01 1999-10-01 New oral formulations IL141762A0 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9821299.6A GB9821299D0 (en) 1998-10-01 1998-10-01 Organic compounds
GBGB9821298.8A GB9821298D0 (en) 1998-10-01 1998-10-01 Organic compoundsq
GBGB9826654.7A GB9826654D0 (en) 1998-12-03 1998-12-03 Organic compounds
GBGB9827624.9A GB9827624D0 (en) 1998-12-16 1998-12-16 Organic compounds
GBGB9907822.2A GB9907822D0 (en) 1999-04-06 1999-04-06 Organic compounds
GBGB9907823.0A GB9907823D0 (en) 1999-04-06 1999-04-06 Organic compounds
PCT/EP1999/007298 WO2000019985A2 (en) 1998-10-01 1999-10-01 New sustained release oral formulations

Publications (1)

Publication Number Publication Date
IL141762A0 true IL141762A0 (en) 2002-03-10

Family

ID=27547321

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14176299A IL141762A0 (en) 1998-10-01 1999-10-01 New oral formulations
IL141762A IL141762A (en) 1998-10-01 2001-03-01 Oral pharmacy preparations with controlled release of rivastigmine

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL141762A IL141762A (en) 1998-10-01 2001-03-01 Oral pharmacy preparations with controlled release of rivastigmine

Country Status (23)

Country Link
US (5) US20010033866A1 (cs)
EP (1) EP1121104B1 (cs)
JP (1) JP4012689B2 (cs)
KR (1) KR100603900B1 (cs)
CN (1) CN1406126A (cs)
AT (1) ATE286725T1 (cs)
AU (1) AU764866B2 (cs)
BR (1) BR9914251A (cs)
CA (1) CA2342340C (cs)
CZ (1) CZ302888B6 (cs)
DE (1) DE69923200T2 (cs)
ES (1) ES2237163T3 (cs)
HK (1) HK1052473A1 (cs)
HU (1) HUP0103883A3 (cs)
ID (1) ID27504A (cs)
IL (2) IL141762A0 (cs)
NO (1) NO331689B1 (cs)
NZ (1) NZ510683A (cs)
PL (1) PL196945B1 (cs)
PT (1) PT1121104E (cs)
SK (1) SK285250B6 (cs)
TR (1) TR200100931T2 (cs)
WO (1) WO2000019985A2 (cs)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0103883A3 (en) 1998-10-01 2002-11-28 Novartis Ag New sustained release oral formulations
US7939522B1 (en) * 1998-11-23 2011-05-10 Bonnie M Davis Dosage formulations for acetylcholinesterase inhibitors
CA2380333A1 (en) * 1999-08-26 2001-03-01 Christian Andina Pharmaceutical formulations
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
JP5049450B2 (ja) * 2000-09-29 2012-10-17 アボツト・ヘルスケア・プロダクツ・ベー・ブイ イオン強度に依存しない徐放性製薬組成物
JP5023412B2 (ja) * 2001-05-09 2012-09-12 吉澤石灰工業株式会社 ホルムアルデヒド廃液の処理剤
PT1424997E (pt) * 2001-09-14 2008-02-28 Scolr Inc Forma de dosagem de libertação prolongada modulada por aminoácidos
JP2005525299A (ja) * 2001-09-14 2005-08-25 スコラー インコーポレイテッド アミノ酸調節性の長期放出投薬形態
KR100453288B1 (ko) * 2002-03-12 2004-10-21 한국화학연구원 약물의 제어 방출을 위한 스퀴즈-유형의 삼투성 약물 전달장치
AU2003266967B2 (en) * 2002-08-07 2006-11-16 Novartis Ag Methods for the treatment of dementia based on Apo E genotype
AU2003100262B4 (en) * 2003-04-07 2003-09-18 Jurox Pty Ltd Stable carprofen composition
US20060105036A1 (en) * 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
PL196544B1 (pl) * 2003-08-08 2008-01-31 Biovail Lab Int Srl Tabletka o zmodyfikowanym uwalnianiu
WO2006020534A2 (en) * 2004-08-09 2006-02-23 Dr. Reddy's Laboratories Ltd. Stabilized desloratadine composition
ES2403069T3 (es) * 2005-02-22 2013-05-13 Sun Pharma Advanced Research Company Ltd Composición oral de liberación controlada que contiene levetiracetam
EP1879583A2 (en) * 2005-05-03 2008-01-23 Mutual Pharmaceutical Company, Inc. Quinine formulations
AU2006285673B2 (en) * 2005-09-01 2010-12-02 Eisai R&D Management Co., Ltd. Method for preparation of pharmaceutical composition having improved disintegratability
GB0525461D0 (en) * 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
GB0606562D0 (en) * 2006-03-31 2006-05-10 Novartis Ag Organic compounds
JP5230613B2 (ja) 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
RU2492175C2 (ru) 2007-04-02 2013-09-10 Теракос, Инк. Бензиловые производные гликозидов и способы их применения
ITMI20071502A1 (it) * 2007-07-25 2009-01-26 Archimica Srl Procedimento per la preparazione di formulazioni solide a rilascio controllato contenenti oxcarbazepina e formulazioni ottenibili con tale procedimento
WO2009022345A1 (en) * 2007-08-14 2009-02-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for the treatment of multiple sclerosis
EP2187742B1 (en) 2007-08-23 2017-10-25 Theracos Sub, LLC (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol derivatives for use in the treatment of diabetes
EP2197454A4 (en) * 2007-09-25 2012-07-04 Idexx Lab Inc PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
TWI523652B (zh) 2008-07-15 2016-03-01 泰瑞克公司 氘化苄基苯衍生物及使用方法
CN105237502A (zh) 2008-08-22 2016-01-13 泰拉科斯萨伯有限责任公司 制备sglt2抑制剂的方法
ES2554375T3 (es) 2008-11-25 2015-12-18 University Of Rochester Inhibidores de las MLK y métodos de uso
ES2746480T3 (es) * 2009-09-18 2020-03-06 Chase Pharmaceuticals Corp Combinación para tratar demencia de tipo Alzheimer
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
CN101797236B (zh) * 2010-03-23 2012-05-23 西南大学 重酒石酸卡巴拉汀口腔崩解片及其制备方法
WO2011149950A2 (en) 2010-05-24 2011-12-01 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
WO2012112933A1 (en) 2011-02-18 2012-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
SG194605A1 (en) * 2011-05-06 2013-12-30 Glaxosmithkline Llc Sustained release paracetamol formulations
EP2709597A2 (en) 2011-05-13 2014-03-26 Emotional Brain B.V. Drug delivery system
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CN104053785A (zh) 2011-11-14 2014-09-17 综合医院公司 为患有抑郁症的受试者选择治疗方案的测定法和方法
IN2015DN01706A (cs) 2012-09-05 2015-05-22 Chase Pharmaceuticals Corp
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
MX368099B (es) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
DK3033082T3 (da) 2013-08-16 2021-09-20 Univ Maastricht Behandling af kognitiv svækkelse med pde4-hæmmer
WO2015136446A1 (en) 2014-03-11 2015-09-17 Nestec S.A. Methods for selecting antidepressant drug therapy to treat depression
CN103877063A (zh) * 2014-03-24 2014-06-25 张绪伟 一种重酒石酸卡巴拉汀胶囊及其制备方法
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
SI3263106T1 (sl) 2015-02-25 2024-02-29 Eisai R&D Management Co., Ltd. Postopek zatiranja grenkobe derivata kinolina
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
KR101990951B1 (ko) * 2015-04-27 2019-06-20 주식회사 네비팜 리바스티그민 함유 서방출 의약조성물
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
WO2019039836A2 (ko) * 2017-08-22 2019-02-28 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물
KR20190036370A (ko) 2017-09-27 2019-04-04 서원대학교산학협력단 약물의 서방성 제형을 위한 약물전달체
HUE065984T2 (hu) * 2018-07-30 2024-07-28 Biothea Pharma Inc Kristályos epinefrin-malonát só
CN112546037A (zh) * 2020-12-08 2021-03-26 苏州大学 卡巴拉汀在制备抗辐射药中的应用
CN113398273B (zh) * 2021-05-14 2022-07-19 广西壮族自治区中国科学院广西植物研究所 木聚糖衍生物作为亲水性缓释材料在制备药物缓释片中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
USRE34990E (en) * 1986-08-07 1995-07-04 Ciba-Geigy Corporation Oral therapeutic system having systemic action
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
DE3922167A1 (de) * 1988-04-16 1991-01-17 Sanol Arznei Schwarz Gmbh Oral zu verabreichende diltiazemhydrochlorid enthaltende pharmazeutische zubereitung zur einmal taeglichen applikation und verfahren zu deren herstellung
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
GB9701695D0 (en) 1997-01-28 1997-03-19 De Beers Ind Diamond Insert for an abrasive tool
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
EP0914098B1 (en) * 1997-05-30 2003-10-01 Osmotica Corp. Multi-layered osmotic device
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
HUP0103883A3 (en) * 1998-10-01 2002-11-28 Novartis Ag New sustained release oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders

Also Published As

Publication number Publication date
ES2237163T3 (es) 2005-07-16
IL141762A (en) 2010-06-30
CZ20011155A3 (cs) 2001-08-15
EP1121104B1 (en) 2005-01-12
BR9914251A (pt) 2001-06-19
NZ510683A (en) 2003-09-26
NO331689B1 (no) 2012-02-27
US6565883B2 (en) 2003-05-20
US20030039692A1 (en) 2003-02-27
CN1406126A (zh) 2003-03-26
CZ302888B6 (cs) 2012-01-11
KR20010073168A (ko) 2001-07-31
NO20011471L (no) 2001-03-22
SK4392001A3 (en) 2002-07-02
EP1121104A2 (en) 2001-08-08
HK1052473A1 (zh) 2003-09-19
DE69923200D1 (de) 2005-02-17
CA2342340A1 (en) 2000-04-13
JP2002526402A (ja) 2002-08-20
TR200100931T2 (tr) 2001-10-22
JP4012689B2 (ja) 2007-11-21
AU6332199A (en) 2000-04-26
US20050175706A1 (en) 2005-08-11
US20070053982A1 (en) 2007-03-08
KR100603900B1 (ko) 2006-07-25
CA2342340C (en) 2006-08-29
NO20011471D0 (no) 2001-03-22
DE69923200T2 (de) 2005-12-22
PL196945B1 (pl) 2008-02-29
WO2000019985A3 (en) 2000-07-20
US20030203025A1 (en) 2003-10-30
PT1121104E (pt) 2005-05-31
ATE286725T1 (de) 2005-01-15
US20010033866A1 (en) 2001-10-25
SK285250B6 (sk) 2006-09-07
AU764866B2 (en) 2003-09-04
WO2000019985A2 (en) 2000-04-13
HUP0103883A2 (hu) 2002-05-29
ID27504A (id) 2001-04-12
HUP0103883A3 (en) 2002-11-28
PL348734A1 (en) 2002-06-03

Similar Documents

Publication Publication Date Title
IL141762A0 (en) New oral formulations
MY129356A (en) Electrospun pharmaceutical compositions
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
YU22399A (sh) Čvrsti farmaceutski sastavi koji obuhvataju ciklosporin i anjonsko površinski-aktivno sredstvo
EP0960621A3 (en) Pharmaceutical formulations comprising sildenafil
MXPA02003321A (es) Composiciones de liberacion controlada que comprenden nimesulida.
IL133397A0 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
ZA200003121B (en) Flash-melt oral dose formulations.
AU2001283563A1 (en) Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
HUP0202495A3 (en) Stable medicinal compositions for oral use
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
PL346764A1 (en) New oral formulation for 5-ht4
AP2003002763A0 (en) Controlled release formulations for oral administration
ZA200308221B (en) Pharmaceutical compositions for oral and topical administration.
WO2002026191A3 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
ZA200108001B (en) Processes for making pharmaceutical oral ECB formulations and compositions.
MY128759A (en) Oral controlled release formulations
PL348202A1 (en) Pharmaceutically active composition and dispensing device
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
PL325509A1 (en) Therapeutic agent for oral administration
GB9902812D0 (en) Composition for delivering pharmaceutically active agents
AU5249500A (en) Medicinal composition for oral administration
SI1041984T1 (en) Pharmaceutical composition for oral administration
MY152490A (en) New oral formulation
GB9806139D0 (en) Combined aspirin and destrogenic compound pharmaceutical formulation for oral contraception or hormone replacement therapy